Generic placeholder image

Current Pharmaceutical Biotechnology


ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Antidote Control of Aptamer Therapeutics: The Road to a Safer Class of Drug Agents

Author(s): K. M. Bompiani, R. S. Woodruff, R. C. Becker, S. M. Nimjee and B. A. Sullenger

Volume 13, Issue 10, 2012

Page: [1924 - 1934] Pages: 11

DOI: 10.2174/138920112802273137

Price: $65


Aptamers, or nucleic acid ligands, have gained clinical interest over the past 20 years due to their unique characteristics, which are a combination of the best facets of small molecules and antibodies. The high binding affinity and specificity of aptamers allows for isolation of an artificial ligand for theoretically any therapeutic target of interest. Chemical manipulations of aptamers also allow for fine-tuning of their bioavailability, and antidote control greatly expands their clinical use. Here we review the various methods of antidote control of aptamer therapeutics – matched oligonucleotide antidotes and universal antidotes. We also describe the development, recent progress, and potential future therapeutic applications of these types of aptamer-antidote pairs.

Keywords: Anticoagulant, antidote, antiplatelet, aptamer, oligonucleotide antidote, therapeutic, universal antidote, nucleic acid ligands, small molecules, antibodies, aptamer-antidote pairs, viral RNA, oligonucleotides, therapeutic target, clinical interest.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy